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Abstract
Introduction: Nonsteroidal anti-inflammatory drugs are recommended for the relief of pain associated with hand
osteoarthritis (OA) but do not alter the underlying structural changes that contribute to impaired physical function.
The current analysis examined the relationship of pain relief with measures of function and global rating of disease
in patients with hand OA.
Methods: This was a combined analysis of 2 prospective, randomized, double-blind, 8-week, multicenter, parallel-
group studies comparing diclofenac sodium 1% gel with placebo gel (vehicle) in patients with radiographically
confirmed mild to moderate hand OA. Patients (n = 783) aged ≥ 40 years applied diclofenac sodium 1% gel (2 g)
or vehicle to each hand 4 times daily for 8 weeks. Outcome measures included pain intensity assessed on a 100-
mm Visual Analog Scale (VAS); the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) subscales for pain,
stiffness, and physical function (100-mm VAS); and a global rating of disease (100-mm VAS). Change in VAS pain
intensity from baseline to week 8 was categorized (<0%, 0%-<15%, 15%-<30%, 30%-<50%, 50%-<70%, and ≥ 70%)
without regard to treatment and compared in each category with the mean change from baseline in each
AUSCAN subindex and the global rating of disease. Pearson correlations between changes in outcome measures
from baseline to week 8 were calculated.
Results: Changes in VAS pain intensity were accompanied by similar changes in AUSCAN scores and global rating
of disease. Pearson correlations confirmed significant associations (P < 0.001) between change in VAS pain intensity
and changes in AUSCAN pain (correlation coefficient [r] = 0.81), AUSCAN function (r = 0.75), AUSCAN stiffness
(r = 0.66), and global rating of disease (r = 0.76).
Conclusions: Pain relief correlated with improvements in physical function, stiffness, and global rating of disease in
patients with hand OA, irrespective of treatment. This suggests that pain or anticipation of pain inhibits physical
function and influences patient perception of disease severity in hand OA. These results also suggest that any
intervention to relieve the pain of hand OA may improve function and patient perception of disease severity,
despite the absence of a disease-modifying mechanism of action.
Trial registration: Clinicaltrials.gov NCT00171652, NCT00171665.
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Hand osteoarthritis (OA) has an estimated prevalence of
20% to 30% [1,2], making the hand the second most fre-
quent site of OA pain [1,3]. The prevalence of hand OA
increases with age, surpassing 50% after patients reach
the age of 60 years [4-6]. Symptoms include not only
pain but also functional impairment in the form of stiff-
ness, reduced grip strength, reduced hand mobility, and
difficulty performing dexterous tasks [2,4,7,8].
Function is irreversibly compromised in OA of the
hand as articular surfaces are eroded and deformed. In
O Ao ft h ek n e ea n dh i p ,ad e f i n i t i v ei m p r o v e m e n ti n
function can be obtained with surgical replacement of
the joint, but prosthetic joints have been less successful
for hand OA [9]. More often, surgery for hand OA may
be performed for cosmetic reasons rather than to pro-
vide functional improvement (for example, patients self-
conscious of and eager to remove Heberden nodes).
Nonsteroidal anti-inflammatory drugs (NSAIDs) are
recommended for the management of pain in patients
with hand OA who do not respond to physical measures
and acetaminophen [10]. Though effective for the treat-
ment of mild to moderate OA pain [11], NSAIDs have
been associated with an increase in the risk of serious
gastrointestinal adverse events, including ulcers, perfora-
tions, and bleeding related to dose and duration of use
[12,13]. The potential risk of cardiovascular [14-16] and
renal [17,18] adverse events with NSAIDs is also consid-
ered exposure-related and generally observed during
long-term NSAID therapy.
Treatment guidelines recommend topical NSAIDs as
effective monotherapy for relief of OA pain in superfi-
cial joints, such as those in the hands [10], with the
potential to mitigate the risk of NSAID-related adverse
events by reducing systemic NSAID exposure. Topical
diclofenac sodium 1% gel provided safe and effective
pain relief compared with placebo in a large clinical trial
in patients with hand OA [19]. Administration of diclo-
fenac sodium 1% gel results in substantially lower sys-
temic diclofenac concentrations than occur following
oral administration [20].
NSAIDs relieve OA pain but are not believed to alter
the underlying changes that produce biomechanical lim-
itations of physical function in OA. However, other
interventions that provide symptomatic relief without
altering underlying structural changes, such as opioids,
have been associated with improvement of physical
function in OA of the knee and hip [21]. This finding
suggests that in addition to the biomechanical limita-
tions caused by hypertrophic changes in OA, it is possi-
ble that pain or the anticipation of pain leads to
voluntary and involuntary restriction of activity [22]. If
this is true, relief of pain alone may improve physical
function in OA although no biomechanical improve-
ment has occurred. In the present analysis, we tested
the hypothesis that pain relief is associated with
improved physical function in patients with hand OA.
Materials and methods
Study design
This was an analysis of pooled data from two similar 8-
week, randomized, double-blind, parallel-group, multi-
center trials comparing diclofenac sodium 1% gel with
vehicle gel in patients with mild to moderate hand OA.
Efficacy and safety results for one of these studies have
been presented elsewhere [19]. Ethical approval was
obtained from an independent ethics committee or insti-
tutional review board for all participating study sites
(Ärztekammer Berlin for study sites in Germany,
CCPPRB de Paris Pitié Salpétrière for study sites in
France, and Quorum Review, Inc. [Seattle, WA, USA]
for study sites in the US). The studies were conducted
in accordance with the Declaration of Helsinki, Directive
91/507/EEC of the Rules Governing Medicinal Products
in the European Community, and US 21 Code of Fed-
eral Regulations (parts 50 and 56) dealing with clinical
studies. All patients provided written informed consent
before participating.
Patients
Patients included men and women at least 40 years old
w h oh a dad i a g n o s i so fp r i m a r yh a n dO Ab yA m e r i c a n
College of Rheumatology criteria [23], with symptoms
including pain for at least 12 months previously, radio-
graphically confirmed to be of mild to moderate severity
(Kellgren-Lawrence grades 1 to 3). At screening, patients
had to have pain more than 15 days during the previous
30 days and must have had at least one painful episode
treated with an NSAID or salicylate during the previous
year. Patients also had to be able to indicate right- or
left-handed dominance and to have reported that pain
was greater in the dominant hand, which was the target
hand. At baseline, patients had to have pain in their tar-
get hand during the previous 24 hours rated at least 40
mm on a 100-mm Visual Analog Scale (VAS). If washed
o u tf r o mN S A I D s ,p a t i e n t sh a dt oh a v ea na tl e a s t
15-mm pain increase between the screening and base-
line visits. Pain scores had to be at least 20 mm lower in
the nondominant hand relative to the dominant hand.
Main exclusion criteria were secondary post-traumatic
OA, history or evidence (or both) of any other rheumatic
disease involving the potential target hand or the arm,
symptomatic OA at additional locations besides the hand
(s) requiring any symptomatic or disease-modifying drug,
adult juvenile chronic arthritis (that is, juvenile chronic
arthritis with continued activity in adulthood), history of
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rheumatoid arthritis, history of other inflammatory dis-
eases (such as colitis) within the previous year, or a his-
tory of fibromyalgia within the previous year.
Randomization and treatment regimen
After screening, patients meeting inclusion criteria
washed out previous analgesics for 1 week or at least
five half-lives of the previous analgesic, whichever was
longer. After washout, patients were randomly assigned
(1:1 ratio) in a double-blind fashion to treatment with
diclofenac sodium 1% gel (Voltaren® Gel; Endo Pharma-
ceuticals Inc., Chadds Ford, PA, USA) or vehicle. To
that end, randomization numbers were allocated to cen-
ters in blocks to balance treatment allocation within
each center.
Patients were assigned to receive 4 g diclofenac
sodium 1% gel (2 g to each hand) or vehicle gel four
times daily for 8 weeks. Diclofenac sodium 1% gel con-
tains diclofenac sodium and its vehicle, which consists
of isopropyl alcohol, propylene glycol, cocoyl caprylo-
caprate, mineral oil, ammonia solution, perfume cream
45/3, carbomer homopolymer type C, polyoxyl 20 cetos-
tearyl ether, and purified water. Vehicle gel was identical
to diclofenac sodium 1% gel in composition but did not
include the active ingredient, diclofenac sodium. The
two gels were identical in feel, appearance, and smell.
Treatments were dispensed in kits containing six 50-g
tubes of study medication (diclofenac sodium gel or
vehicle) for a 2-week supply. Use of acetaminophen res-
cue medication was allowed up to a maximum daily
dose of 4 g. However, rescue medication was not
allowed within 36 hours of assessments. Disease-modify-
ing drugs, muscle relaxants, additional analgesics, and
alternative therapies (for example, acupuncture) were
not allowed.
Assessments
Measures of pain intensityw e r ec o m p a r e dw i t hm e a -
sures of physical function and patient global rating of
disease in all patients. Pain intensity in the dominant
hand was assessed on a 100-mm VAS (VAS pain inten-
sity, 0 = no pain, 100 = unbearable pain). Pain, stiffness,
and function were also assessed using the Australian/
Canadian Osteoarthritis Hand Index (AUSCAN), a 15-
item tool that focuses on the functional status of the
dominant hand. Each AUSCAN item was assessed on a
100-mm VAS. Total AUSCAN scores were calculated
for pain (questions 1 to 5), stiffness (question 6), and
function (questions 7 to 15) as averages over the indivi-
dual questions. A global rating of disease was assessed
on a 100-mm VAS (0 = very good; 100 = very poor).
For this assessment, patients responded to the following
item: ‘Considering all the ways osteoarthritis of your
hands affects you, please indicate with an ‘X’ through
the horizontal line how well are you doing’.
Statistical analysis
The purpose of the present analysis was to determine
whether changes in pain were accompanied by similar
changes in function rather than to compare diclofenac
sodium 1% gel with placebo. To that end, data on all
patients who received at least one dose of study medica-
tion were pooled without regard to whether they were
assigned diclofenac sodium 1% gel or placebo. Improve-
ment in VAS pain intensity from baseline to week 8 was
categorized according to percentage change (less than
0%, 0% to less than 15%, 15% to less than 30%, 30% to
less than 50%, 50% to less than 70%, and 70% or more)
without regard to randomized treatment. Within each
VAS pain intensity improvement category, AUSCAN
pain, AUSCAN stiffness, and AUSCAN function subin-
dices and global rating of disease were summarized by
mean change from baseline to week 8. Mean percentage
change from baseline to week 8 was computed by cate-
gory as the mean change from baseline divided by the
mean baseline value. The associations between change
from baseline for VAS pain intensity and changes from
baseline for the three AUSCAN subindices and the glo-
bal rating of disease were also summarized as Pearson
correlations. Postbaseline assessments were conducted
at weeks 1, 2, 4, 6, and 8. For patients who terminated
prematurely, the final available assessment was used
instead of the week 8 assessment.
Results
Patients
Of 1,252 patients screened, 783 were randomly assigned
to receive diclofenac sodium 1% gel (n = 400) or vehicle
(n = 383) (Figure 1). In all, 701 (89.5%) patients com-
pleted the study. All 783 were included in the correla-
tion analysis. The majority of patients were female
(80.2%) and white (93.6%) (Table 1). Mean (standard
deviation [SD]) VAS pain intensity (71.1 [15.1] mm) was
moderate to severe. Mean scores on the three AUSCAN
subindices and global rating of disease also reflected
moderate pain, functional impairment, and impact of
disease on patients’ sense of well-being. Nearly half of
the patients (46.1%) had Kellgren-Lawrence grade 3 OA,
indicating moderate rather than mild anatomic disease
(Table 2), but baseline mean VAS pain intensity scores
were similar (approximately 70 mm) for each grade. In
addition, mean changes from baseline through week 8
in VAS pain intensity, on the three AUSCAN subin-
dices, and global rating of disease were similar for
patients with Kellgren-Lawrence grades 1, 2, and 3.
Most patients had radiographic evidence of sclerosis
(63.3%), joint space narrowing (78.0%), and osteophytes
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cysts. A majority (58%) had a pain reduction of at least
30%. At least 10% of patients fell within each of the
pain reduction categories (Table 3).
Efficacy
Mean changes from baseline in AUSCAN and global rat-
ing of disease scores were consistent with changes in VAS
pain intensity (Figure 2). When VAS pain intensity scores
improved, AUSCAN subscale scores and global rating of
disease showed similar improvement. At one extreme,
patients showing little or no improvement (0% to less than
15%) in VAS pain intensity had little or no mean (SD)
improvement in AUSCAN pain (1.5 [12.2] mm; 2.2%),
AUSCAN function (1.4 [11.7] mm; 1.9%), AUSCAN stiff-
ness (0.4 [17.5] mm; 0.6%), and global rating of disease
(-0.8 [13.8] mm; -1.3%). At the other extreme, patients
with at least 70% improvement in VAS pain intensity had
large mean (SD) improvements in AUSCAN pain (48.3
[20.1] mm; 76.9%), AUSCAN function (45.9 [22.9] mm;
71.2%), AUSCAN stiffness (44.9 [25.5] mm; 75.2%), and
global rating of disease (43.8 [21.1] mm; 78.1%). Patients
whose VAS pain intensity worsened over the 8-week treat-
ment period also experienced worsening of mean (SD)
scores for AUSCAN pain (-5.8 [12.5] mm; -8.8%), AUS-
CAN function (-4.0 [12.6] mm; -5.9%), AUSCAN stiffness
(-3.3 [22.7] mm; -5.4%), and global rating of disease (-8.22
[20.4] mm; -14.2%).
Pearson correlations confirmed the association
between change in VAS pain intensity and changes in
AUSCAN scores and global rating of disease (Table 4).
Change in VAS pain intensity was found to be highly
Assessed for eligibility (n=1252)
Randomized (n=783)
Allocated to receive diclofenac sodium 1% gel (n=400)
Received allocated intervention (n=400)
Allocated to receive vehicle gel (n=383)
Received allocated intervention (n=383)
Completed treatment (n=354)
Discontinued treatment (n=46)
    Adverse events (n=19)
    Lack of efficacy (n=11)
    Withdrew consent (n=8)
    Other (n=8)
Completed treatment (n=347)
Discontinued treatment (n=36)
    Lack of efficacy (n=17)   
    Adverse events (n=9)
    Withdrew consent (n=7)
    Other (n=3)
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Figure 1 CONSORT diagram describing study pooling and post-hoc analysis in relation to original study design.
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coefficient [r] = 0.81), AUSCAN function (r = 0.75),
AUSCAN stiffness (r = 0.66), and global rating of dis-
ease (r = 0.76).
Discussion
In this analysis, we found that improvements in pain in
patients treated with diclofenac sodium 1% gel or vehi-
cle for symptomatic hand OA were accompanied by
similar improvements in measures of functional status
and patients’ overall rating of OA disease status. Our
study population included patients with mild to moder-
ate hand OA (Kellgren-Lawrence grades 1 to 3), most of
whom had structural changes that typically contribute
to functional impairment in OA. Mean VAS pain inten-
sity was moderate to severe.
The similarity of mean changes in pain and functional
impairment scores that we observed across Kellgren-
Lawrence severity grades 1, 2, and 3 is consistent with
research showing that radiographic findings in hand OA
are only modestly associated with reports of pain and
weakly associated with functional disability [4]. The
strong association observed between pain and function in
our study suggests an important role for symptomatic
treatment in improving the functional status of patients
with hand OA of mild to moderate radiographic severity.
Impairment of joint function in patients with hand
OA is of great concern because of its impact on many
activities of daily living and almost every type of
employment. Unfortunately, effective disease-modifying
interventions to slow or reverse the structural changes
that impair function in hand OA have not yet been
found. Modest results have been obtained in some stu-
dies of chondroitin sulfate [24-26] and doxycycline [27].
Although surgical interventions of joint replacement
and resurfacing of the knee or hip have been quite suc-
cessful [28] and associated with improved function and
quality of life [29], outcomes in smaller joints, such as
those in the hand, have been less successful [30-33]. In
the absence of modalities to prevent or reverse the
structural changes contributing to functional impair-
ment in hand OA, it is important to determine whether
relief of pain alone can improve function in this
population.
The observed correlation in our analysis between
reductions in pain and improvements in function sug-
gests that some functional restriction associated with
h a n dO As t e m sf r o mp a t i e n t sv o l u n t a r i l yo r
Table 1 Baseline demographics and assessments
Diclofenac
sodium 1% gel
Vehicle Combined
n = 400 n = 383 n = 783
Percentage of female
patients
79.3 81.2 80.2
Percentage of white
patients
93.0 94.3 93.6
Age, years
Mean (SD) 63.8 (10.0) 64.1 (9.7) 63.9 (9.8)
Range 40-92 40-87 40-92
Body mass index, kg/m
2
Mean (SD) 27.5 (5.4) 27.5 (5.6) 27.5 (5.5)
Range 17.4-55.0 14.3-49.8 14.3-55.0
VAS pain intensity
Mean (SD) 71.1 (15.3) 71.1 (14.8) 71.1 (15.1)
Range 26-100 4-100 4-100
AUSCAN pain
Mean (SD) 63.9 (17.5) 63.4 (17.7) 63.7 (17.6)
Range 11.6-98.4 10.4-99.0 10.4-99.0
AUSCAN stiffness
Mean (SD) 60.4 (24.7) 59.7 (25.7) 60.0 (25.2)
Range 1-98 0-100 0-100
AUSCAN function
Mean (SD) 65.9 (18.1) 64.6 (18.8) 65.3 (18.4)
Range 8.9-98.7 8.3-99.2 8.3-99.2
Global rating of disease
Mean (SD) 56.9 (18.1) 56.7 (18.7) 56.8 (18.4)
Range 5-97 9-98 5-98
AUSCAN, Australian/Canadian Osteoarthritis Hand Index; SD, standard
deviation; VAS, Visual Analog Scale.
Table 2 Baseline radiographic evaluations
Disease characteristic Diclofenac
sodium 1% gel
Vehicle Combined
n = 400 n = 383 n = 783
Kellgren-Lawrence grade
1 70 (17.5) 54 (14.1) 124 (15.8)
2 141 (35.2) 157 (41.0) 298 (38.1)
3 189 (47.3) 172 (44.9) 361 (46.1)
Sclerosis 251 (62.7) 245 (64.0) 496 (63.3)
Subchondral cysts 153 (38.2) 149 (38.9) 302 (38.6)
Joint space narrowing 317 (79.2) 294 (76.8) 611 (78.0)
Osteophytes 305 (76.2) 308 (80.4) 613 (78.3)
Values are presented as number (percentage).
Table 3 Frequency distribution for pain intensity
improvement
Pain reduction category Patients, number (percentage)
Less than 0% 85 (10.9)
0% to less than 15% 158 (20.2)
15% to less than 30% 83 (10.6)
30% to less than 50% 100 (12.8)
50% to less than 70% 110 (14.0)
70% or more 247 (31.5)
Total 783 (100.0)
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anticipated pain and not solely from the biomechanical
limitations of affected joints. Neither diclofenac sodium
1% gel nor its vehicle is believed to influence structural
changes in hand OA or provide any disease-modifying
benefit. This implies that the observed improvements in
functional outcomes and health status occurred in the
absence of structural improvement.
The results of this analysis are consistent with a pre-
vious study that showed an association between pain and
both functional and overall health status in patients with
hand OA [34] and OA of the knee and hip [21]. In a
study assessing the validity of the AUSCAN hand index,
all three AUSCAN subindices were significantly corre-
lated with an independent measure of pain and with grip
strength [34]. As in the present study, the independent
Figure 2 Mean (standard deviation) changes in (a) Australian/Canadian Osteoarthritis Hand Index (AUSCAN) pain, (b) AUSCAN
function, (c) AUSCAN stiffness, and (d) global rating of disease from baseline to week 8 by pain intensity category.
Table 4 Correlations between changes in outcome measures from baseline to week 8
VAS pain intensity AUSCAN pain AUSCAN stiffness AUSCAN function Global rating of disease
VAS pain intensity 1.00 0.81
a 0.66
a 0.75
a 0.76
a
AUSCAN pain 1.00 0.74
a 0.88
a 0.75
a
AUSCAN stiffness 1.00 0.75
a 0.60
a
AUSCAN function 1.00 0.71
a
Global rating of disease 1.00
aP < 0.001. AUSCAN, Australian/Canadian Osteoarthritis Hand Index; VAS, Visual Analog Scale.
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AUSCAN pain subindex, but correlations with the func-
tion and stiffness subindices were nearly as strong.
Our results are also consistent with two trials asses-
sing patients with OA of the knee or hip. In a 12-week
placebo-controlled trial of the long-acting opioid trama-
dol extended release [21], reductions in pain associated
with knee or hip OA were significantly correlated with
improvements in measures of function (the Western
Ontario and McMaster Universities Osteoarthritis
Index) and health status (the Short Form-36 Health Sur-
vey [SF-36]). Similarly, in a study of diclofenac sodium
1% gel, pain reduction in knee OA was accompanied by
and significantly correlated with improvements in Wes-
tern Ontario and McMaster Universities Osteoarthritis
Index stiffness and physical function indices and in a
global rating of disease [35]. As in our study, patients in
these studies received no concurrent disease-modifying
drugs, reinforcing the idea that observed effects of pain
reduction on functional outcomes and health status
occurred in the absence of structural improvement.
Our analysis differed from the study of tramadol in
that we assessed pain and function in hand OA and
evaluated health status using a global rating of disease
instead of the SF-36. SF-36 is a broad rating of overall
health status, whereas the global rating of disease speci-
fically asks patients to rate the impact of OA on their
daily lives. Thus, our results establish a link between
pain, physical function, and patients’ sense of how well
they are coping with hand OA.
Current guidelines for the management of hand OA
do not recommend opioids but do suggest that studies
be conducted to assess and compare the efficacy of acet-
aminophen, weak opioids (such as tramadol), and oral
NSAIDs in this population [10]. According to these
guidelines, local treatments, such as topical NSAIDs,
should be considered for the management of pain, parti-
cularly in patients who have mild to moderate OA.
Results from the present analysis suggest that pain
reductions during treatment with a topical therapy may
also be accompanied by improvements in functional sta-
tus and general sense of well-being in patients with mild
to moderate hand OA.
A limitation of our study is that it was only 8 weeks.
Hand OA is a chronic disease that may require treatment
over several decades. Long-term trials would be necessary
to determine whether the association between analgesia
and functional improvement is maintained over time.
Another limitation of our study is that we have not con-
sidered possible variations in response between subpopu-
lations with different affected hand joints (for example,
first carpometacarpal versus interphalangeal OA). Finally,
because this was a post hoc analysis, the results should be
considered exploratory. The validity of the results would
be strengthened if similar correlations could be found in
other studies employing a variety of designs, especially
those with alternative measures of pain and function,
conducted for other purposes.
Conclusions
Improvements in the pain of hand OA were associated
with substantial improvements in physical function, stiff-
ness, and overall rating of OA disease status, without
regard to active versus placebo treatment. Diclofenac
sodium 1% gel is indicated for relief of OA pain in joints
amenable to topical treatment, such as the hands and
knees. The placebo gel has no therapeutic indication.
This suggests that pain or anticipation of pain inhibits
physical function and influences patient perception of
disease severity in hand OA. These results also suggest
that any intervention to relieve the pain of hand OA
may improve function and patient perception of disease
severity, despite the absence of a disease-modifying
mechanism of action.
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